CEC Capital Wins GBC 2025 "Biomanufacturing Industry Annual Award"; Partner Dr. Jane Liao Delivers Keynote Speech

CEC Capital has been honored with the "Biomanufacturing Industry Annual Award" at GBC 2025, hosted by Vbdata, in recognition of its outstanding research capabilities and strong industry influence in the field of biomanufacturing. Dr. Jane Liao, Partner at CEC Capital and Head of the Synthetic Biology Practice, was invited to attend the conference and deliver a keynote address.

Since 2024, CEC Capital has led several landmark transactions in synthetic biology and biomanufacturing, including high-profile financings for MoonBiotech, Microcyto, and QLBiopharm. These deals rank among the largest and most influential in the sector. Notably, MoonBiotech’s Series C financing marked the largest-ever fundraising in China’s agricultural microbiology space, while Microcyto’s 300 million RMB Series A round was also a key milestone in the market.

Through systematic industry research and professional private equity advisory services, CEC Capital has firmly established itself as a leading investment bank in biomanufacturing, making synthetic biology a core pillar of its strategic focus.